← Product Code [MQK](/productcode/MQK) · K262276

# Cyperus (K262276)

_Contrario Medical, Inc. · MQK · Oct 26, 2026 · Obstetrics/Gynecology · SESE_

**Canonical URL:** https://fda.innolitics.com/device/K262276

## Device Facts

- **Applicant:** Contrario Medical, Inc.
- **Product Code:** [MQK](/productcode/MQK.md)
- **Decision Date:** Oct 26, 2026
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 884.6160
- **Device Class:** Class 2
- **Review Panel:** Obstetrics/Gynecology

## Indications for Use

Cyperus is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.

## Device Story

Cyperus is a sterile, single-use sperm separation device used by reproductive health clinic personnel. It processes human semen samples to isolate motile sperm for ART procedures. The device features a lower chamber for semen injection and an upper chamber for sperm buffer and collection. Operation involves adding liquefied semen to the base, placing filter layers, adding separation medium, and incubating at 37°C for 30 minutes. The device leverages the natural motility of sperm to swim up and across filters into the upper chamber. The output is an optimized motile sperm sample collected by the clinician, which is then used for ICSI, IVF, or IUI. This process benefits patients by providing a concentrated, high-motility sperm sample, potentially improving ART outcomes.

## Clinical Evidence

Bench testing only. Performance testing evaluated the separation of motile sperm from raw semen. Results showed an increase in motile sperm from 65.47% to 100.0% and progressive motile sperm (PMSC) from 58.73% to 97.33%. Sterilization validated per ISO 11137-1. Package integrity and transport testing performed per ASTM D4332-22, ASTM D4169-22, ASTM F1886/F1886M-16, ASTM F88/F88M-23, and F2096-11. Endotoxin levels <20 EU/device per USP <85>. Human Sperm Survival Assay (HSSA) confirmed ≥80% control motility at 24 hours.

## Technological Characteristics

Dimensions: 39.2mm x 77.2mm x 13.6mm; Weight: 14g. Materials: Polycarbonate, cellulose acetate, polymethylmethacrylate. Principle: Passive sperm migration (swim-up) through filter layers. Sterilization: Radiation (SAL 10^-6). Shelf-life: 3 months. No electronic components or software.

## Regulatory Identification

Assisted reproduction labware consists of laboratory equipment or supplies intended to prepare, store, manipulate, or transfer human gametes or embryos for in vitro fertilization (IVF), gamete intrafallopian transfer (GIFT), or other assisted reproduction procedures. These include syringes, IVF tissue culture dishes, IVF tissue culture plates, pipette tips, dishes, plates, and other vessels that come into physical contact with gametes, embryos or tissue culture media.

## Special Controls

*Classification.* Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, and clinical testing). The device, when it is a dish or plate intended for general assisted reproduction technology procedures, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.

## Predicate Devices

- LensHooke CA1 Sperm Separation Device, LensHooke CA0 Sperm Separation Device ([K221810](/device/K221810.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{1}

![LOGO](FDA U.S. FOOD & DRUG ADMINISTRATION)

October 26, 2026

Contrario Medical, Inc.
% Allison Komiyama
Consultant
DuVal & Associates
825 Nicollet Mall
Suite 1820
Minneapolis, Minnesota 55402

Re: K262276
Trade/Device Name: Cyperus
Regulation Number: 21 CFR 884.6160
Regulation Name: Assisted Reproduction Labware
Regulatory Class: II
Product Code: MQK
Dated: September 23, 2026
Received: September 25, 2026

Dear Allison Komiyama:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: The Center for Devices and Radiological Health (CDRH) does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, the Food and Drug Administration (FDA may publish further announcements concerning your device in )the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{2}

K262276 - Allison Komiyama

Page 2

Before making any change significantly affecting the safety or effectiveness of the device, you must submit a new premarket notification in accordance with 21 CFR 807.81. Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the

{3}

K262276 - Allison Komiyama

Page 3

Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# REBECCA DORSEY -S

For

Monica D. Garcia, Ph.D.

Assistant Director

DHT3B: Division of Reproductive,

Gynecology, and Urology Devices

OHT3: Office of Gastrorenal, ObGyn,

General Hospital, and Urology Devices

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

Enclosure

{4}

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

# Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 07/31/2026

See PRA Statement below.

510(k) Number (if known)

K262276

Device Name

Cyperus

Indications for Use (Describe)

Cyperus is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.

Type of Use (Select one or both, as applicable)

☑

Prescription Use (Part 21 CFR 801 Subpart D)

☐

Over-The-Counter Use (21 CFR 801 Subpart C)

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services

Food and Drug Administration

Office of Chief Information Officer

Paperwork Reduction Act (PRA) Staff

PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (8/23)

Page 1 of 1

PSC Publishing Services (301) 443-6740

EF

{5}

K262276

Page 1 of 4

# 510(k) Summary

# K262276

## 1. Submitter Information

Dr. Albert Huang

Contrario Medical, Inc.

2450 Holcombe Blvd. Suite 1420, Houston, TX 77021 United States

Telephone: (832) 799-8546

Email: albert@contrariomedical.com

## 2. Submission Correspondent

Allison Komiyama

DuVal & Associates

825 Nicollet Mall, Suite 1820, Minneapolis, MN 55402 United States

Telephone: (612) 338-7170

Email: komiyama@duvalfdalaw.com

## 3. Date of Summary

October 26, 2026

## 4. Device Identification

Device Trade Name: Cyperus

Common Name: Sperm Separation Device

Regulation Name: Assisted Reproduction Labware

Regulation Number: 21 CFR 884.6160

Device Class: Class II

Product Code: MQK

## 5. Predicate Device

Device Trade Name: LensHooke CA1 Sperm Separation Device, LensHooke CA0

Sperm Separation Device

510(k) Number: K221810

The predicate device has not been subject to a design-related recall.

## 6. Device Description

Cyperus is used by lab personnel of reproductive health clinics to process human semen samples. The device helps to separate and allow collection of motile sperm for assisted reproductive technology (ART) procedures. The sterile single-use device leverages natural behavior of sperm to swim.

{6}

K262276

Page 2 of 4

The Cyperus device is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures. The Cyperus device dimensions are 39.2mm x 77.2mm x 13.6mm and when empty, weighs 14 grams. There is a lower chamber with an inlet port where the semen sample is injected into, and an upper chamber where the sperm buffer is added and where the final optimized sperm sample is removed after incubation.

### 7. Indications for Use

Cyperus is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures.

### 8. Comparison of Technological Characteristics with the Predicate Device

The table below compares the intended use and technological characteristics of the subject and predicate device.

Table 1: Intended Use and Technological Characteristics Comparison

|  Characteristic/Feature | Subject Device | Predicate  |
| --- | --- | --- |
|  510(k) Number | K262276 | K221810  |
|  Device Name | Cyperus | LensHooke CA1 Sperm Separation Device, LensHooke CA0 Sperm Separation Device  |
|  Sponsor Name | Contrario Medical Inc. | Bonraybio Co., Ltd.  |
|  Regulation Number Product Code Device Class | 884.6160 MQK Class II | 884.6160 MQK Class II  |
|  Design | A disposable device containing a base, two filter layers, a port for semen loading, an upper chamber with removable lid for media loading and sperm collection after processing. The top filter is for sperm separation, while the bottom one is used for the collection of excess fluid. | A disposable device containing a base, filter layer(s), and a port on the filter for media loading and sperm collection after processing. -CA0 with one filer layer -CA1 with two filter layers  |
|  Indications for Use | Cyperus is intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro fertilization (IVF) and intrauterine insemination (IUI) procedures. | The LensHooke CA0 Sperm Separation Device and the LensHooke CA1 Sperm Separation Device are intended for preparing motile sperm from semen for use in the treatment of infertile couples by intracytoplasmic sperm injection (ICSI), in vitro  |

{7}

K262276

Page 3 of 4

|   |  | fertilization (IVF) and intrauterine insemination (IUI) procedures.  |
| --- | --- | --- |
|  Mechanism of Action | Liquefied semen is added to the base. The filter(s) are placed on the base and separation medium added through the layer port. The loaded device is incubated at 37°C for 30 minutes to allow motile sperm to swim up and across the filter(s) to migrate into the separation medium in the upper filter layer. | Liquefied semen is added to the base. The filter(s) are placed on the base and separation medium added through the layer port. The loaded device is incubated at 37°C for 30 minutes to allow motile sperm to swim up and across the filter(s) to migrate into the separation medium in the upper filter layer.  |
|  Materials | Polycarbonate, cellulose acetate, and polymethylmethacrylate | Polycarbonate  |
|  Sterility | Radiation sterilized (SAL 10^{-6}) | Radiation sterilized (SAL 10^{-6})  |
|  HSSA | ≥80% of the control motility at 24 h after exposure for 30 min | ≥80% of the control motility at 24 h after exposure for 30 min  |
|  Endotoxin (LAL) | <20 EU/device | <20 EU/device  |
|  Shelf-life | Three months | Two years (24-months)  |

The subject device has a similar mechanism of action and design as the predicate device, relying on sperm motility to separate motile sperm from non-motile sperm or non-sperm cells in a closed container. However, the predicate device has several filter options (e.g., one or two filters). The devices differ in materials and shelf-life. These differences in technology do not raise different questions of safety and effectiveness and can be evaluated through performance testing.

### 9. Summary of Non-Clinical Performance Testing:

The following tests were conducted on the subject device to support a determination of substantial equivalence to the predicate device:

- Sterilization validation study per ISO 11137-1:2006/(R) 2015, Sterilization of health care products - Radiation - Part 1: Requirements for the development, validation and routine control of a sterilization process for medical devices
- Package integrity and transportational testing after accelerated aging to the end of the three month shelf-life duration. Testing included the following:

- Environmental conditioning per ASTM D4332-22, Standard Practice for Conditioning Containers, Packages, or Packaging Components for Testing
- Simulated shipping distribution per ASTM D4169-22, DC-13, Standard Specification for Performance Testing of Shipping Containers and Systems
- Package integrity testing consisting of:

- Visual inspection per ASTM F1886/F1886M-16
- Seal strength per ASTM F88/F88M-23
- Bubble leak testing per F2096-11

- Endotoxin testing per USP <85>: <20 EU/device

{8}

K262276

Page 4 of 4

- Human Sperm Survival Assay (HSSA) before and after accelerated aging to support a three month shelf-life: ≥80% of the control motility at 24 h after exposure for 30 min
- Performance testing:

The subject device was used to separate motile sperm cells from raw semen samples. The separation procedures followed the Instructions for Use, and the percentage of motile sperm cells in the harvested output samples were compared to the input samples. A summary of the results is provided in Table 2 below:

Table 2: Summary of Results

|  Device name | % motile sperm (before/after separation) | % change in total motility | % progressive motile sperm (PMSC) (before/after separation | % change in PMSCs  |
| --- | --- | --- | --- | --- |
|  Cyperus | 65.47%/100.0% | 34.53% | 58.73%/97.33% | 38.6%  |

### 9. Conclusions

The results of performance testing described above demonstrate that Cyperus is as safe and effective as the predicate device and supports a determination of substantial equivalence.

---

**Source:** [https://fda.innolitics.com/device/K262276](https://fda.innolitics.com/device/K262276)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com
